Article
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
European journal of haematology - 1 Jul 2021
Bouvier Anne, Hamel Jean-François, Delaunay Jacques, Delabesse Eric, Dumas Pierre-Yves, Ledoux Marie-Pierre, Peterlin Pierre, Luquet Isabelle, Roth Guepin Gabrielle, Bulabois Claude Eric, Gallego Hernanz Maria Pilar, Guillerm Gaëlle, Guieze Romain, Hicheri Yosr, Simand Célestine, Himberlin Chantal, Hunault-Berger Mathilde, Bernard Marc, Jourdan Eric, Caillot Denis, Dorvaux Véronique, Tavernier Emmanuelle, Daguindau Etienne, Banos Anne, Ojeda-Uribe Mario, Gyan Emmanuel, Alexis Magda, Marolleau Jean-Pierre, Turlure Pascal, Bouscary Didier, Humbrecht Catherine, Zerazhi Hacène, Béné Marie-Christine, Pigneux Arnaud, Carre Martin, Ifrah Norbert, Blanchet Odile, Vey Norbert, Récher Christian, Cornillet-Lefèbvre Pascale
Abstract excerpt
In this randomized phase 3 study, the FILO group tested whether the addition of 6 mg/m2 of gemtuzumab ozogamycin (GO) to standard chemotherapy could improve outcome of younger patients with de novo acute myeloid leukemia (AML) and intermediate-risk cytogenetics. GO arm was prematurely closed after 254 inclusions because of toxicity. A similar complete remission rate was observed in both arms. Neither event-free...
Read the complete abstract on PubMed